OPGN currently looks like its in a rising wedge pattern, which usually break downward. I've been in since $1.75, averaged up to about $1.97. With volume it could make another run for the $2.50's, if rejected it could break downward out of the wedge and revisit the $2.10 area. Might get close to a golden cross by that time as well.
Fundamentally, the company has a...
My outlook on where this might go short term a few catalysts in the pipeline including potentially FDA approval could send this well over $5 based on share structure (low float of about 18.14M shares). from what I understand this has a similar product to BNGO. BNGO market cap = $1.8B - OPGN market cap = $47.45M all Just my opinion always DYODD
So returns compounds at:
1.75X 2X 2.25X 2.39X
OpGen, Inc., a precision medicine company, engages in developing molecular information products and services in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening...
Possible move:20-60%+
Reward/Risk: 10(R/R>3 is Ideal)
Time frame: 12wks
This is just my technical view, not a fundamental comment..!
I can make you confused by a crowded messy chart, but I would rather simple effective presentations..!
Leave a comment that is helpful or encouraging. Let's master the markets together
Looking for EW continuation here from the move back in March. Although my concern is that we're stuck in a bearish penant with the lower high back in August @ 4.50.
I'm neutral/bullish here but may take some time to see any movement.
OpGen up 62% on availability of rapid COVID-19 blood test
rockets northward on a massive 74x surge in volume in apparent response to its post on social media that it is offering a 10-minute COVID-19 IgG/IgM test kit that the FDA has approved for emergency use during the pandemic.
finance.yahoo.com
www.marketwatch.com
6/9/2020 Alliance Global Partners Reiterated Rating to Buy and target price to $5.00
OpGen, Inc. is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease.
Aug 11 Reuters:
OpGen Group Company Ares Genetics Demonstrates Feasibility of CLIA-compliant Next Generation Sequencing Workflow for...
